Rabeprazole
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H527039

CAS#: 117976-89-3

Description: Rabeprazole is an inhibitor of H(+)-K(+)-exchanging atpase in gastric parietal cells.

Chemical Structure

img
Rabeprazole
CAS# 117976-89-3
Instruction

Theoretical Analysis

Hodoodo Cat#: H527039
Name: Rabeprazole
CAS#: 117976-89-3
Chemical Formula: C18H21N3O3S
Exact Mass: 359.13
Molecular Weight: 359.440
Elemental Analysis: C, 60.15; H, 5.89; N, 11.69; O, 13.35; S, 8.92

Price and Availability

Size Price Availability Quantity
10mg USD 350 2 weeks
25mg USD 640 2 weeks
Bulk inquiry

Synonym: Rabeprazole

IUPAC/Chemical Name: 2-[[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole

InChi Key: YREYEVIYCVEVJK-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)

SMILES Code: O=S(C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCCCOC)=C3C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 359.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sue S, Ogushi M, Arima I, Kuwashima H, Nakao S, Naito M, Komatsu K, Kaneko H, Tamura T, Sasaki T, Kondo M, Shibata W, Maeda S. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. Helicobacter. 2017 Dec 21. doi: 10.1111/hel.12456. [Epub ahead of print] PubMed PMID: 29271026.

2: Rochoy M, Dubois S, Glantenet R, Gautier S, Lambert M. [Gastric acid rebound after a proton pump inhibitor: Narrative review of literature]. Therapie. 2017 Oct 26. pii: S0040-5957(17)30159-2. doi: 10.1016/j.therap.2017.08.005. [Epub ahead of print] French. PubMed PMID: 29195714.

3: Toda R, Shiramoto M, Komai E, Yoshii K, Hirayama M, Kawabata Y. Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers. J Clin Pharmacol. 2017 Nov 28. doi: 10.1002/jcph.1038. [Epub ahead of print] PubMed PMID: 29193126.

4: Kinoshita Y, Kato M, Fujishiro M, Masuyama H, Nakata R, Abe H, Kumagai S, Fukushima Y, Okubo Y, Hojo S, Kusano M. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study. J Gastroenterol. 2017 Nov 29. doi: 10.1007/s00535-017-1417-z. [Epub ahead of print] PubMed PMID: 29188387.

5: Zheng SQ, Hong XD, Chen TS, Luo PF, Xiao SC. [Effects of caspase-1 inhibitor VX765 on cold-restraint stress-induced acute gastric ulcer in mice]. Zhonghua Shao Shang Za Zhi. 2017 Nov 20;33(11):688-693. doi: 10.3760/cma.j.issn.1009-2587.2017.11.006. Chinese. PubMed PMID: 29166711.

6: Iliou K, Malenović A, Loukas YL, Dotsikas Y. Analysis of potential genotoxic impurities in rabeprazole active pharmaceutical ingredient via Liquid Chromatography-tandem Mass Spectrometry, following quality-by-design principles for method development. J Pharm Biomed Anal. 2018 Feb 5;149:410-418. doi: 10.1016/j.jpba.2017.11.037. Epub 2017 Nov 12. PubMed PMID: 29154196.

7: Kahramanoğlu Aksoy E, Pirinçci Sapmaz F, Göktaş Z, Uzman M, Nazlıgül Y. Comparison of Helicobacter pylori Eradication Rates of 2-week Levofloxacin Containing Triple Therapy, Levofloxacin Containing Bismuth Quadruple Therapy and Standard Bismuth Quadruple Therapy as a First-line Regimen. Med Princ Pract. 2017 Nov 3. doi: 10.1159/000484930. [Epub ahead of print] PubMed PMID: 29131124.

8: Giri N, Lam LH, LaBadie RR, Krzyzaniak JF, Jiang H, Hee B, Liang Y, Shaik MN. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers. Cancer Chemother Pharmacol. 2017 Dec;80(6):1249-1260. doi: 10.1007/s00280-017-3472-9. Epub 2017 Oct 30. PubMed PMID: 29086063.

9: Kamat N, Pai G, Mallayasamy SR, Kamath A, S R. Direct costs for nonsurgical management of Chronic Pancreatitis in a tertiary care teaching hospital. Expert Rev Pharmacoecon Outcomes Res. 2017 Oct 12:1-6. doi: 10.1080/14737167.2018.1386560. [Epub ahead of print] PubMed PMID: 29022830.

10: Graham DY, Tansel A. Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clin Gastroenterol Hepatol. 2017 Sep 28. pii: S1542-3565(17)31168-0. doi: 10.1016/j.cgh.2017.09.033. [Epub ahead of print] PubMed PMID: 28964908.

11: Li MJ, Li Q, Sun M, Liu LQ. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. Medicine (Baltimore). 2017 Sep;96(39):e8120. doi: 10.1097/MD.0000000000008120. PubMed PMID: 28953640; PubMed Central PMCID: PMC5626283.

12: Hu JL, Yang J, Zhou YB, Li P, Han R, Fang DC. Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China. Saudi J Gastroenterol. 2017 Sep-Oct;23(5):275-280. doi: 10.4103/sjg.SJG_91_17. PubMed PMID: 28937021; PubMed Central PMCID: PMC5625363.

13: Zhang H, Yang Z, Ni Z, Shi Y. A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease. Gastroenterol Res Pract. 2017;2017:9865963. doi: 10.1155/2017/9865963. Epub 2017 Aug 22. Review. PubMed PMID: 28912807; PubMed Central PMCID: PMC5585660.

14: Khashaba PY, Ali HRH, El-Wekil MM. A rapid Fourier transform infrared spectroscopic method for analysis of certain proton pump inhibitors in binary and ternary mixtures. Spectrochim Acta A Mol Biomol Spectrosc. 2018 Feb 5;190:10-14. doi: 10.1016/j.saa.2017.09.003. Epub 2017 Sep 5. PubMed PMID: 28889052.

15: Srinivas NR. Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury. Aliment Pharmacol Ther. 2017 Oct;46(7):706-707. doi: 10.1111/apt.14240. PubMed PMID: 28880446.

16: Nuki Y, Esaki M. Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury-authors' reply. Aliment Pharmacol Ther. 2017 Oct;46(7):708. doi: 10.1111/apt.14264. PubMed PMID: 28880441.

17: Takeuchi T, Takahashi Y, Kawaguchi S, Ota K, Harada S, Kojima Y, Sakamoto H, Kuramoto T, Kojima K, Sanomura M, Hoshimoto M, Higashino T, Itabashi T, Takada K, Sakaguchi M, Tominaga K, Kusano M, Higuchi K. Therapy of GERD and FD overlap with symptoms after usual-dose PPI: acotiamide plus usual-dose PPI vs. double-dose PPI. J Gastroenterol Hepatol. 2017 Sep 1. doi: 10.1111/jgh.13970. [Epub ahead of print] PubMed PMID: 28865098.

18: Hillman L, Yadlapati R, Thuluvath AJ, Berendsen MA, Pandolfino JE. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus. 2017 Sep 1;30(9):1-15. doi: 10.1093/dote/dox055. PubMed PMID: 28859358.

19: Nagata Y, Nagasaka K, Koyama S, Murase M, Saito M, Yazaki T, Komatsu N, Murase T, Uehara T, Taniuchi N. Successful eradication of Helicobacter pylori with a herbal medicine, goshuyuto (Wu Zhu Yu Tang), plus rabeprazole after failure of triplet therapy with vonoprazan: a report of three cases. J Dig Dis. 2017 Aug 28. doi: 10.1111/1751-2980.12537. [Epub ahead of print] PubMed PMID: 28845910.

20: Kwon S, Lee DH, Kang JB, Kim N, Park YS, Shin CM, Yoon H, Choi YJ. [The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in Helicobacter pylori Eradication]. Korean J Gastroenterol. 2017 Aug 25;70(2):72-80. doi: 10.4166/kjg.2017.70.2.72. Korean. PubMed PMID: 28830132.